Notre offre FCPI Truffle InnoCroissance 2015 et Mandat de gestion

The fast pace of innovation in IT offers compelling investment opportunities

Truffle Capital is a pioneer investor in the exciting field of Energy

Biotechnology has radically transformed medicine over the past 25 years


  • “ Truffle Capital has been an industrial, strategic and financial partner to Vexim since the creation of the company in 2006 and has enabled Vexim to acquire an international role within the treatment of spine fractures. The Truffle Capital partners are passionate entrepreneurs, keen on innovation and understand a company’s needs and its people. They have taken measured risks, helped Vexim in fulfilling its aims and accompanied us in our progress, for which we are very grateful. ”Vexim
    Vincent Gardes / CEO

Truffle Capital is an independent European venture capital firm

Established in 2001, Truffle Capital, with €700 million under management and advisory via institutional and retail private equity funds as of December 30th 2014, Truffle Capital is an important and independent European private equity firm, specialised in investments in the Information Technology and Life Sciences sectors, in spin-offs and companies developping breakthrough technologies and products. Every year Truffle Capital launch a new FCPI fund (mutual fund investing in innovative companies). The firm is led by a team of three General Partners with decades of successful investment and entrepreneurial experience in both Europe and in the USA.

Backed by an investment team of international experts and an experienced support team, a total of 17 professionals, Truffle Capital aims to achieve superior financial returns by leveraging its industry knowledge, extensive network, and operational experience to identify business opportunities that match latent market needs.

Truffle CapitalonGoogle+


09-2015

CARMAT

3rd September 2015 – 3rd patient implanted with a CARMAT heart at the Georges Pompidou European Hospital has returned home

Pdf


+ read more
09-2015

RETENCY

2nd September 2015 – Retency accelerates its development with €5 million in financing from Truffle Capital

Pdf


+ read more
09-2015

DEINOVE

2nd September 2015 – Deinove produces muconic acid from 2G substrates

Pdf


+ read more
09-2015

VAXIN

1st September 2015 – Vaxin changes company name to Altimmune
Pdf


+ read more